

**OMTM, Volume 5**


**Supplemental Information**

**Spatially and Temporally Regulated *NRF2***

**Gene Therapy Using *Mcp-1* Promoter**


**in Retinal Ganglion Cell Injury**

**Kosuke Fujita, Koji M. Nishiguchi, Yukihiro Shiga, and Toru Nakazawa**



**Figure S1. Localization of Sytox-positive cells in AAV2-CMV-eGFP transduced retina following ONC.**

Retinal flat-mount prepared at 5 days after ONC showing co-localization of EGFP (labeled by AAV2/2.CMV.EGFP) and Sytox Orange following ONC. The arrowheads designate Sytox-positive cells in which CMV promoter is activated. Vector was injected at 2.0  $\mu\text{L}$  ( $1.0 \times 10^{12}$  gc/ mL) per injection. Scale bar: 20  $\mu\text{m}$ .



**Figure S2. Analysis of the eyes treated with AAV2/2.CMV.EGFP and the eyes without treatment following ONC**

qRT-PCR analysis of RGC marker genes. There was no difference in the levels of RGC mRNA marker expression between the eyes with AAV2/2.CMV.EGFP and the eyes without treatment (No inj) following ONC. Values are expressed relative to the non-treated eye at 7 days after ONC ( $N = 6$ /group). The vector was injected at  $2.0 \mu\text{L}$  ( $1.0 \times 10^{12}$  gc/ mL) per injection. Data represent means  $\pm$  S.E.M.,  $*P < 0.05$ . ns, not significant.